Pimecrolimus: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Pimecrolimus. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Pharyngitis streptococcal | 1% |
| Staphylococcal infection | 1% |
| Skin papilloma | 1% |
| Eye infection nos | 1% |
| Sinus congestion | 1% |
| Wheezing | 1% |
| Constipation | 1% |
| Loose stools | 1% |
| Urticaria | 1% |
| Acne nos | 1% |
| Accident nos | 1% |
| Laceration | 1% |
| Back pain | 1% |
| Bacterial infection | 0% |
| Pneumonia nos | 0% |
| Molluscum contagiosum | 0% |
| Herpes simplex | 0% |
| Tonsillitis nos | 0% |
| Viral infection nos | 0% |
| Gastroenteritis nos | 0% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
ELIDEL ® (pimecrolimus) Cream 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. ELIDEL Cream is not indicated for use in children less than 2 years of age (see WARNINGS, boxed WARNING, and PRECAUTIONS, Pediatric Use).
Medical disclaimer: Always consult a qualified healthcare professional about any medication.